Webinar Date/Time: Tue, Dec 5, 2023 11:00 AM EST
Learn more about measuring droplet size distribution during the in-process analysis of pharmaceutical emulsions.
Register Free: https://www.biopharminternational.com/bp_w/droplet-size-analysis
Event Overview:
The droplet size distribution in pharmaceutical emulsions is a critically important physical parameter. This webinar will discuss why the droplet size is important and how to measure it in the lab and with a new in-process size analyzer.
Key Learning Objectives:
Who Should Attend:
Lab chemists, manufacturing engineers, PAT scientists and engineers, particle size analysis experts
Speaker:
Mark Bumiller
Technology Manager
Entegris, Inc.
Mark Bumiller has worked in the field of particle size analysis for over 40 years. Positions held include Product Manager at Hiac Royco, Technical Support Manager and Vice President of Business Development at Malvern Instruments, Vice President of Particle Products at Horiba, and Technology Manager at Entegris. He has served as a member of the PDA expert committee on subvisible particulate matter testing, executive committee of the International Fine Particle Research Institute (IFPRI), and the Particle Technology Forum of the American Institute of Chemical Engineers. Mark is an active member of Technical Committee 24 within ISO, helping to write standards for particle size and zeta potential analysis.
Register Free: https://www.biopharminternational.com/bp_w/droplet-size-analysis
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.